Do quality of life, physical function, or the Wheatley index at diagnosis predict 1-year mortality with intensive chemotherapy in older acute myeloid leukemia patients?

Timilshina, Narhari; Breunis, Henriette; Tomlinson, George; Brandwein, Joseph; Alibhai, Shabbir M.H.

doi:10.1016/j.leukres.2016.06.001

Cited by 17 publications

(9 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, promising candidate characteristics based on estimates of effect include measures of self-reported physical function and history of falls. Functional measures have been associated with survival in hematologic malignancies in many but not all studies investigating this domain [6,7,31,45]. Data collected in this study can be used to support development of fully powered multisite studies investigating individual risk factors and risk profiles derived from GA.…”

Section: Methodsmentioning

confidence: 95%

Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance)

Klepin

Ritchie

Major‐Elechi

et al. 2020

Journal of Geriatric Oncology

View full text Add to dashboard Cite

a b s t r a c tObjective: To demonstrate feasibility of performing geriatric assessment (GA) in the National Clinical Trials Network (NCTN) and to explore the utility of GA to characterize treatment tolerance. Materials and methods: We conducted a multisite companion study (CALGB 361006) to CALGB 11001, a phase 2 trial of adults ≥60 years old with newly diagnosed FLT3-mutated AML, testing the efficacy of adding sorafenib to intensive chemotherapy. On 361006, a GA was administered prior to induction and prior to post-remission therapy. The GA is divided into items requiring administration by a health care professional (HCP) and patient selfadministered questionnaires. Feasibility outcomes were recruitment rate, time to GA completion, difficulty with GA administration, percent of patients requiring assistance, and satisfaction. Change in GA measures preand post-induction were compared using Wilcoxon signed rank test and McNemar's tests. Results: The recruitment rate was 80% (N = 43, median age 68 years). Median completion time of the GA was 30 min; (10 and 21 min for HCP and patients, respectively). HCP reported no difficulty completing assessments (100%). Most patients completed questionnaires without assistance (77%), and were satisfied with the length (89%). Self-reported physical function, mental health, social activity and nutritional parameters worsened after induction. Conclusion: GA is feasible to administer in the setting of intensive induction for older adults with AML in the NCTN and provides evidence of the impact of induction therapy on physical and emotional health.

show abstract

Section: Methodsmentioning

confidence: 95%

Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance)

Klepin

Ritchie

Major‐Elechi

et al. 2020

Journal of Geriatric Oncology

View full text Add to dashboard Cite

show abstract

“…The prognostic value of patient‐reported health status for AML is less clear. One study in Italy reports a positive association between patient‐reported QoL scores and survival of elderly adults with AML [ 10 ], whereas in Canada, the same association has not been made [ 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Quality of life and socioeconomic indicators associated with survival of myeloid leukemias in Canada

Cressman

Hogge

Minden

et al. 2020

eJHaem

View full text Add to dashboard Cite

Understanding how patient‐reported quality of life (QoL) and socioeconomic status (SES) relate to survival of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) may improve prognostic information sharing. This study explores associations among QoL, SES, and survival through administration of the Euro‐QoL 5‐Dimension, 3‐level and Functional Assessment of Cancer Therapy‐Leukemia and financial impact questionnaires to 138 adult participants with newly diagnosed AML or MDS in a longitudinal, pan‐Canadian study. Cox regression and lasso variable selection models were used to explore associations among QoL, SES, and established predictors of survival. Secondary outcomes were changes in QoL, performance of the QoL instruments, and lost income. We found that higher QoL and SES were positively associated with survival. The Lasso model selected the visual analog scale of the EQ‐5D‐3L as the most important predictor among all other variables (P = .03; 92% selection). Patients with AML report improved QoL after treatment, despite higher mean out‐of‐pocket expenditures compared with MDS (up to $599 CDN/month for AML vs $239 for MDS; P = .05), greater loss of productivity‐related income (reaching $1786/month for AML vs $709 for MDS; P < .05), and greater caregiver effects (65% vs 35% caregiver productivity losses for AML vs MDS; P < .05). Our results suggest that including patient‐reported QoL and socioeconomic indicators can improve the accuracy of survival models.

show abstract

“…[1,5] Despite of the development of new potential therapies over the past years, the prognosis of R/R AML patients remains poor with a 3-year overall survival (OS) at no more than 10%. [6][7][8] Besides, R/R AML treatments, such as intensive chemotherapy and bone marrow transplantation, are aggressive and correlated with severe adverse events, long hospitalization and high costs, which leads to a marked deterioration of quality of life and psychological problems such as fear of death, social isolation, increased anxiety and depression in R/R AML patients. [9,10] Therefore, it is essential to closely monitor the psychological disorders especially anxiety and depression in R/R AML patients.…”

Section: Introductionmentioning

confidence: 99%

The prevalence, risk factors, and prognostic value of anxiety and depression in refractory or relapsed acute myeloid leukemia patients of North China

Hao²,

Cong

et al. 2019

Medicine

View full text Add to dashboard Cite

This study aimed at investigating the prevalence of anxiety and depression, and their risk factors as well as their correlation with prognosis in refractory or relapsed (R/R) acute myeloid leukemia (AML) patients.A total of 180 R/R AML patients were enrolled and their anxiety and depression were assessed by Hospital Anxiety and Depression Scale (HADS) before treatment. Besides, HADS was also evaluated in 180 de novo AML patients prior treatment and 180 healthy controls (HCs), respectively.Both the HADS-Anxiety and HADS-Depression scores were increased in R/R AML patients compared with de novo AML patients and HCs (all P < .001). Meanwhile, the prevalence of anxiety and depression was 53.9% and 45.6% in R/R AML patients, which were also greatly higher compared with de novo AML patients and HCs (all P < .01). Regarding risk factors, higher Eastern Cooperative Oncology Group score and lines of salvage therapy were correlated with anxiety and depression in R/R AML patients (all P < .05). Furthermore, anxiety and depression were associated with shorter overall survival (OS) in R/R AML patients (all P < .05), while no association of different degrees of anxiety and depression with OS was observed (all P > .05).Anxiety and depression are highly prevalent and implicated in the management and prognosis of R/R AML.

show abstract

Do quality of life, physical function, or the Wheatley index at diagnosis predict 1-year mortality with intensive chemotherapy in older acute myeloid leukemia patients?

Cited by 17 publications

References 33 publications

Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance)

Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance)

Quality of life and socioeconomic indicators associated with survival of myeloid leukemias in Canada

The prevalence, risk factors, and prognostic value of anxiety and depression in refractory or relapsed acute myeloid leukemia patients of North China

Contact Info

Product

Resources

About